

NATIONAL EPIDEMIOLOGICAL STUDY OF ACUTE MYELOID LEUKEMIA (AML) IN ALGERIA OVER A PERIOD OF 5 YEARS (2006-2010)

A multicentric cooperative study of the AML and Myelodysplasia Algerian Work Group


Bekadja MA, (National Group Coordinator), Hamladji RM (CPMC, Alger), Belhani M (CHU Benimessous, Alger), Ardjoun FZ (HCA, Alger), Abad MT(CAC Blida), Touhami H (CHU Oran), Ait Ali H (CHU Tizi Ouzou), Zouaoui Z (CHU Sidi Bel Abbes), Sidimansour N (CHU Constantine), Mesli N (CHU Tlemcen), Hamdi S (CHU Sétif), Grifi F (CHU Annaba), Saidi M (CHU Batna), Bachiri A (HMRU Oran)



L'editorial

Intérêt des premières études épidémiologiques effectuées sur une période de 10 ans (1995 à 2004) en Algérie dans le domaine de l'Hématologie.

Rose Marie Hamladji



www.hematologie-dz.com

- ① Première étude nationale, 1995 – 2005 : M. BENAKLI
(Revue Algérienne d'Hématologie N° 00)



**APPROCHE EPIDEMIOLOGIQUE DES LEUCEMIES AIGUES
MYELOIDES EN ALGERIE** Travail coopératif et multicentrique sur 1877 cas (1995-2005)

M. BENAKLI

① Groupe Algérien d'Etude des LAM / MDS

- i. Etat des lieux
- ii. Prise en charge consensuelle diagnostique et thérapeutique
- iii. Système d'information sanitaire (data fiables pour stratégie de soin)

② Deuxième étude nationale, 2006 – 2010

original research report

A population-based study of the epidemiology and clinical features of adults with acute myeloid leukemia in Algeria: report on behalf of the Algerian Acute Leukemia Study Group

Mohamed Amine Bekadja,^a Rose Marie Hamladji,^b Meriem Belhani,^c Fatima Zohra Ardjoun,^d Mohand Tayeb Abad,^e Hadj Touhami,^f Hocine Ait-Ali,^g Zahia Zouaoui,^h Nouredine Sidimansour,ⁱ Selma Hamdi,^j Fatiha Grifi,^k Naima Mesli,^l Mahdia Saldi,^m Nemra Mehalhal,ⁿ Aissa Bachiri,^o Rachid Bouhass,^p Yousuf Mohamed Said,^q Nouri Midoun^r

From the ^aClinic of Hematology and Cell Therapy, EHU 1st November, Oran, ^bClinic of Hematology and Bone Marrow Transplant, Centre Pierre et Marie Curie Algiers, ^cClinic of Hematology, University Hospital Beni Mesous, Algiers, ^dClinic of Hematology, University Hospital, Hôpital Central des Armées-Ain Naadja, ^eClinic of Hematology, Center of Cancer, Blida, ^fClinic of Hematology University Hospital, Centre Hospitalo-Universitaire Oran, ^gClinic of Hematology University Hospital, Tizi Ouzou, ^hClinic of Hematology University Hospital Sidi Bel Abbès, ⁱClinic of Hematology University Hospital Constantine, ^jClinic of Hematology University Hospital, Setif, ^kClinic of Hematology University Hospital, Annaba, ^lClinic of Hematology University Hospital, Tlemcen, ^mClinic of Hematology University Hospital, ⁿBatnaclinic of Hematology, Etablissement Public Hospitalier, Mascara, ^oHMRUO, Oran, ^pClinic of Hematology and Cell Therapy, University Hospital Etablissement Hospitalier et Universitaire, 1st November, Oran, Algeria, ^qAdult Hematology-HSCT Program, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia, ^rDepartment of Epidemiology and Biostatistic, University Hospital EHU 1st November, Oran, Algeria.

Correspondence: Bekadja Mohamed Amine - Clinic of Hematology and Cell Therapy, University Hospital Etablissement Hospitalier et Universitaire, 1st November, Oran, Algeria - mabekadja@yahoo.fr - T: 00213-6-61314927, F: 00213 41 42 16 36 - Accepted: November 2011

Hematol Oncol Stem Cel Ther 2011; 4(4): 161-166

STUDY OBJECTIVE

1

AML epidemiological characteristics

2

AML incidence within the Algerian population

3

Survey Impact

PATIENTS and METHODS

- ✓ Pre-established form
- ✓ Diagnosis of acute leukemia
- ✓ Inclusion age (adults)
- ✓ Data collection & processing Centre (EHU)
 - Results
 - ✦ In relation to geographic data
 - ✦ In relation to anthropologic data
 - ✦ In relation to pathology

Pre-established form



ENQUETE EPIDEMIOLOGIQUE NATIONALE PORTANT SUR LES LEUCEMIES AIGUES MYELOÏDES DE 2006 A 2010

Service :	Nom :	Prénom :					
Age au diagnostic :	Sexe : M / F	Wilaya de résidence :					
Origine géographique :	Profession :						
Conditions socio-économiques :							
Bonnes ☐	Moyennes ☐	Précaires ☐					
Antécédents pathologiques de type néoplasique ou non :							
Personnels :		Familiaux :					
Date de diagnostic :							
Moyens diagnostiques :							
Cytologie :							
Cytochimie :	MPO ☐	Noir Soudan ☐	Autres ☐				
Immunophénotypage :	Oui ☐	Non ☐					
Cytogénétique :	Oui ☐	Non ☐					
Biologie moléculaire	Oui ☐	Non ☐					
LAM (CLASSIFICATION) :							
M0 :	M1 :	M2 :	M3 :	M4 :	M5 :	M6 :	M7 :


RESULTS


RESULTS

☑ **IN RELATION TO GEOGRAPHIC DATA**


IN RELATION TO ANTHROPOLOGIC DATA

IN RELATION TO PATHOLOGY





AML distribution according to the place of enrollement



RESULTS

IN RELATION TO GEOGRAPHIC DATA

☒ **IN RELATION TO ANTHROPOLOGIC DATA**

IN RELATION TO PATHOLOGY

Clinical characteristics of patients at diagnosis

	2006 – 2010
Number of Patients	1426
Median age	44,7 (16-82)
• Male	41,1
• Female	44,6
Sex ratio	1,16


RESULTS

IN RELATION TO GEOGRAPHIC DATA


IN RELATION TO ANTHROPOLOGIC DATA

☒ **IN RELATION TO PATHOLOGY**


FREQUENCY OF AML DIAGNOSIS METHODS




AML FREQUENCY ACCORDING TO FAB CLASSIFICATION




AML DISTRIBUTION ACCORDING TO THE YEAR OF DIAGNOSIS



CRUDE ANNUAL AML INCIDENCE (FOR 100 000 Hbts) PER DIAGNOSIS YEAR




AML DISTRIBUTION ACCORDING TO THE AGE-STANDARDIZED INCIDENCE



DISCUSSION

DIAGNOSTIC METHODS



*M. BENAKLI, revue Algérienne hématologie, N°00 mars 2009

AML ANNUAL INCIDENCE


	1995 - 2005 *	2006 - 2010
Number of Patients	1877	1426
Median age	39 (1-92)	44,7 (16-82)
Sex ratio	1,08	1,16
Annual Incidence	0,67 / 100.000 hbts	0,91 / 100.000 hbts

(0,33 on 1995;
0,67 on 2005).


Level of incidence has been doubled within the interval of ten years

**M. BENAKLI, revue Algérienne hématologie, N°00 mars 2009*

DISTRIBUTION OF AML & ALL CASES ACCORDING TO YEAR OF DIAGNOSIS




DISTRIBUTION OF AML \ ALL RATIO ACCORDING TO THE 2 AGE GROUPS




CONCLUSION


STUDY IMPACT ⁽¹⁾



STUDY IMPACT ⁽²⁾







Aknowledgement

Abdennebi N, Belhadri F, Moussaoui, Boukhemia F, Ait Ameer N, Tensaout F, Ahmed Nacer R, Hamladji RM :
Hématologie et GMO CPMC Alger

Kaci Z, BouicheL, Bernine S, Ahmidatou, H, Boutbiba, Hadidi, Boutiba, Achoui, Nekkal S , Belhani: CHU Beni
Messous

Taebi, Attari, Kellouche, Mansour, Sahraoui , Ardjoun FZ : HCA-Ain Naadja

Berraf S, Abad MT : CAC Blida

Zouani S,Touhami H : CHU Oran

Allouda M, Dali N, Ait Ali H: CHU Tizi-Ouzou

Zouaoui Z: CHU Sidi-Bel-Abbès

Osmani S, Bekadja MA: EHU 1er novembre Oran

Himour I, Benhalilou M, Berrahma I, Sidimansour N : CHU Constantine

Dali M, Benkhodja FZ, Bentahar I, Amoura A, Hamdi S : CHU Sétif

Ouled Diaf, Smaili, Grifi F: CHU Annaba

Mesli N: CHU Tlemcen

Saidi M: CHU Batna

Mehalhal N: EPH Mascara

Bachiri A : HMRUO

